Skip to main content
. Author manuscript; available in PMC: 2015 Mar 28.
Published in final edited form as: J Control Release. 2014 Jan 23;178:79–85. doi: 10.1016/j.jconrel.2014.01.012

Figure 6. PCat-siSurvivin did not alter tumor pharmacokinetics of TPM.

Figure 6

Animals were treated as described in Figure 4. Paclitaxel concentrations in tumor tissues were analyzed; the results showed no difference in paclitaxel concentrations for animals receiving single agent TPM or the TPM+PCat-siSurvivin combination (p=0.97, 0.50 and 0.60 for the 96, 120 and 144 hr samples, respectively).